115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion Cancer
    Meeting Abstract

    Rieke, D. T.; Hong, D. S.; Drilon, A.; Tan, D. S.; Lin, J.; Kummar, S.; McDermott, R.; Berlin, J.; Italiano, A.; Lassen, U. N.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Tesch, H.; Tolaney, S.; Bardia, A.; Marmé, F.; Cortes, J.; Schmid, P.; Loirat, D.; Tréedan, O.; Ciruelos, E.; Dalenc, F.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raab, M. S.; Hänel, M.; Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Christofyllakis, K.; Roeker, L.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens
    Meeting Abstract

    Einsele, H.; Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Scheid, C.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Alternative schedule of temozolomide/capecitabine (TEMCAP) administration in patients with neuroendocrine neoplasms
    Meeting Abstract

    Melhorn, P.; Mazal, P.; Wolff, L.; Popov, P.; Kretschmer-Chott, E.; Haug, A.; Mayerhoefer, M. E.; Raderer, M.; Kiesewetter, B.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Risk profiling of patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): 3-year update of the POLARIX study
    Meeting Abstract

    Oellerich, T.; Lenz, G.; Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Trnény, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Rieke, D. T.; Lin, J. I.; Tan, D. S.; Kummar, S.; Patel, J. D.; Cermignani, L.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save